Low booster uptake in cancer patients despite health benefits
Jane C. Figueiredo(University of Southern California), Akil Merchant(University of Southern California), Julia Levy(Cedars-Sinai Medical Center), Inderjit Mehmi, Carissa A. Huynh(Cedars-Sinai Medical Center), V. Krishnan Ramanujan(Cedars-Sinai Medical Center), Andrew Hendifar(Cedars-Sinai Medical Center), Omid Hamid(Cedars-Sinai Medical Center), Alma Patricia González(Cedars-Sinai Medical Center), So Yung Choi(Cedars-Sinai Medical Center), Noah Merin(Cedars-Sinai Medical Center), Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Warren G. Tourtellotte(Cedars-Sinai Medical Center), Alexander M. Xu(Cedars-Sinai Medical Center), Sarah‐Jeanne Salvy(Center for Health and Gender Equity), Kimia Sobhani(Cedars-Sinai Medical Center), Simeon Mahov(Cedars-Sinai Medical Center), Ronald B. Natale(Cedars-Sinai Medical Center), Justin Darrah(Cedars-Sinai Medical Center), Jun Gong(Cedars-Sinai Medical Center), Nathalie Nguyen(Children's Hospital Colorado), Robert Vescio(Royal Adelaide Hospital), Ronald Paquette, Alain C. Mita(Cedars-Sinai Medical Center), Tucker Lemos(Cedars-Sinai Medical Center), Maimoona Nadri(Cedars-Sinai Medical Center)
Cited by 2
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
|New England Journal of Medicine|2003|2.6k